COLL Collegium Pharmaceutical Inc.

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Danielle Jesse                                                                                       

Director, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications

 



EN
24/10/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Provides 2025 Financial Guidance and Business Update

Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 2024, we executed on our prio...

January 8, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies London Healthcare ConferenceFireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date and Time: Thursday, December 5, 2024, at 1:00 p.m. ET The fi...

November 12, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Chief Executive Officer of Collegium – – Conference Call Scheduled for Today at 4:30 p.m. ET ...

November 7, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Appoints Vikram Karnani as Chief Executive Officer

Collegium Appoints Vikram Karnani as Chief Executive Officer Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael Heffernan, who has...

November 7, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Third Quarter 2024 Financial Results on November 7...

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please ...

October 24, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch